China Accepts Junshi Biosciences’ COVID-19 Drug Application

Junshi Biosciences, a Chinese biopharmaceutical company, announced on January 18 that the country’s medical products authorities had accepted a new drug application for Deuremidevir Hydrobromide Tablets (project code: JT001/VV116) for the treatment of COVID-19…
Read More

What's Hot

Snap Health Acquires Leading Healthcare Service Provider Your Therapy Source

HIV treatment fell inexcusably behind due to COVID lockdown

Western Australia To Ban Anti-Gay Conversion Practices

China Accepts Junshi Biosciences’ COVID-19 Drug Application

Corporations try to kill Oklahoma rule that aims to keep medicine by mail from getting too hot or too cold

Peptide 3D-printing inks could advance regenerative medicine

3 Potential Consequences of Ending the COVID Public Health Emergency Status

How Yo X Scaled Through COVID-19 Pandemic To Becoming A Hit Maker

Snap Health Acquires Leading Healthcare Service Provider Your Therapy Source

HIV treatment fell inexcusably behind due to COVID lockdown

Western Australia To Ban Anti-Gay Conversion Practices

Martha Eddy Jentz has been Inducted into the Prestigious Marquis Who’s Who Biographical Registry

Bruce Springsteen and These Lost Years

China’s long-term future with Covid-19 will depend on accurate data

The NIH-led research response to COVID-19 | Science

EdTech and Smart Classrooms Market Size Is Projected to Reach US$ 127.77 Bn and Grow at CAGR 13.56% over Forecasts Period 2023-2030 : Key Players: Apple Inc., Blackboard

China Reports 50% Decrease in COVID-Related Deaths

COVID-19: Saskatoon and Regina’s wastewater virus levels remain on the rise

What's Hot

China Accepts Junshi Biosciences’ COVID-19 Drug Application

Related Posts